For the quarter ending 2025-09-30, IRWD had $47,555K increase in cash & cash equivalents over the period. $47,581K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 40,080 | -13,787 |
| Depreciation and amortization | 475 | 946 |
| Loss on disposal of property and equipment | -7 | -85 |
| Share-based compensation expense | 3,612 | 9,815 |
| Non-cash interest expense | 418 | 832 |
| Non-cash lease expense | 426 | 827 |
| Deferred income taxes | 27,772 | 14,775 |
| Accounts receivable, net | 34,193 | 4,282 |
| Prepaid expenses and other current assets | 248 | 471 |
| Other assets | -63 | -284 |
| Accounts payable and accrued expenses | 10,693 | -4,174 |
| Accrued research and development costs | -1,168 | -2,664 |
| Operating lease liabilities | -603 | -1,156 |
| Other liabilities | 249 | 3,856 |
| Net cash provided by operating activities | 47,583 | 4,886 |
| Purchases of property and equipment | 2 | 33 |
| Net cash used in investing activities | -2 | -33 |
| Proceeds from exercise of stock options and employee stock purchase plan | 0 | 94 |
| Net cash provided by (used in) financing activities | 0 | 94 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -26 | -654 |
| Net increase (decrease) in cash and cash equivalents | 47,555 | 4,293 |
| Cash and cash equivalents at beginning of period | 88,559 | - |
| Cash and cash equivalents at end of period | 140,407 | - |
IRONWOOD PHARMACEUTICALS INC (IRWD)
IRONWOOD PHARMACEUTICALS INC (IRWD)